Argenx advancing ARGX-119 to registrational trial for congenital myasthenic syndromes after positive Phase 1b data.

From Nasdaq.: 2025-06-30 01:36:00

argenx SE plans to advance ARGX-119, a first-in-class agonist antibody targeting muscle-specific kinase, to a registrational study for patients with congenital myasthenic syndromes. This comes after positive topline data from its Phase 1b trial. Congenital Myasthenic Syndromes are rare neuromuscular disorders caused by genetic defects. ARGX-119 is the sixth molecule developed through their Immunology Innovation Program, showcasing their expertise in antibody engineering and deep knowledge of biology. This reflects the company’s commitment to pushing the boundaries of what’s possible in healthcare innovation. Visit rttnews.com for more health news.



Read more at Nasdaq.: Argenx To Advance ARGX-119 To Registrational Trial For Congenital Myasthenic Syndromes